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Guidelines for Overseas Presumptive Treatment of Strongyloidiasis, 
Schistosomiasis, and Soil-Transmitted Helminth Infections  
For Refugees Resettling to the United States 
 
UPDATES--the following are content updates from the previous version of the 
overseas guidance, which was posted in 2008 
 Latin American and Caribbean refugees are now included, in addition to Asian, 
Middle Eastern, and African refugees. 
 Recommendations for management of Strongyloides in refugees from Loa loa-
endemic areas emphasize a screen-and-treat approach and de-emphasize a 
presumptive high-dose albendazole approach.   
 Presumptive use of albendazole during any trimester of pregnancy is no 
longer recommended. 
 Links to a new table for the Treatment Schedules for Presumptive Parasitic 
Infections for U.S.-Bound Refugees, administered by IOM. 
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[This is main body of the web posting] 
 
Summary of Recommendations  
These guidelines are recommendations for the International Organization for Migration 
(IOM) physicians and other panel physicians who administer overseas predeparture 
presumptive treatment for intestinal parasites.  While most recommendations have been 
implemented, not all refugee populations listed in this document are receiving all 
recommended pre-departure medications, due to funding restrictions and logistical 
challenges.  For current implementation status in specific populations, see the Treatment 
Schedules for Presumptive Parasitic Infections for U.S.-Bound Refugees, administered by 
IOM.  The recommendations in these guidelines may also be used by U.S. medical 
providers caring for refugees who will be receiving presumptive treatment after they 
arrive in the United States. 
 
 All Middle Eastern, Asian, North African, Latin American, and Caribbean 
refugees, with exceptions noted in this document, should receive presumptive 
therapy with: 
o Albendazole, single dose of 400 mg (200 mg for children 12-23 months) 
AND 
o Ivermectin, two doses 200 /Kg orally once a day for 2 days before 
departure to the United States. 
 All African refugees who did not originate from or reside in countries where Loa 
loa infection is endemic (Box 1), with exceptions noted in this document, should 
receive presumptive therapy with:  
o Albendazole, single dose of 400 mg (200 mg for children 12-23 months) 
AND 
o Ivermectin, two doses 200 /Kg orally once a day for 2 days AND  
o Praziquantel, 40 mg/kg, which may be divided in two doses before 
refugees depart for the United States. 
 All sub-Saharan African refugees who originated from or resided in countries 
where Loa loa infection is endemic (Box 1), with exceptions noted in this 
document, should receive presumptive therapy with: 
o Albendazole, single dose of 400 mg (200 mg for children 12-23 months) 
AND 
o Praziquantel, 40 mg/kg, which may be divided in two doses before 
departure to the United States. 
o Refugees from Loa loa-endemic countries (Box 1) in Africa should not 
receive presumptive ivermectin for strongyloidiasis prior to departure. 
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Management of Strongyloides should be deferred until arrival in the 
United States, unless Loa loa is excluded by reviewing a daytime (10 AM 
to 2 PM) Giemsa-stained blood smear. Deferral of treatment for 
strongyloides until after the refugee arrives in the United States is 
acceptable. Guidance is available for management of Strongyloides 
following arrival in the United States in the Domestic Intestinal Parasite 
Screening Guidelines. 
 
Background 
In 1997, a Centers for Disease Control and Prevention (CDC) pilot project evaluated 
single-dose albendazole presumptive treatment in U.S.-bound Barawan Somali refugees. 
1
 This project demonstrated decreases in soil-transmitted parasites in refugees who 
received presumptive treatment.  In May 1999, CDC extended this recommendation to all 
refugees resettling from sub-Saharan Africa (SSA) and Asia. In 2008 the 
recommendation was extended to refugees from the Middle East.  Currently, most 
refugees from the countries listed in the Treatment Schedules for Presumptive Parasitic 
Infections for U.S.-Bound Refugees and without a contraindication are receiving a single 
dose of albendazole prior to departure. 
Data increasingly suggest that pre-departure albendazole treatment has dramatically 
decreased the overall prevalence of soil-transmitted helminth infections in refugees.  A 
recent evaluation of more than 26,000 African and Asian refugees demonstrated single-
dose albendazole resulted in an absolute reduction of the prevalence of any soil-
transmitted helminth from 20.8% to 4.7%, as measured by stool ova and parasite 
examination.
2
 These findings support previous data in African refugees resettling to the 
United States, showing a similar decrease in soil-transmitted helminths following 
implementation of pre-departure albendazole treatment. 
3
  Despite this documented 
decrease in the overall prevalence of soil-transmitted helminth infections, a single dose of 
albendazole has very limited effect on infection with Strongyloides and no effect against 
Schistosoma spp. 
2, 4, 5
 
Due to documented high rates of infection in refugee populations and increasing reports 
of serious clinical consequences, in 2005 CDC issued recommendations for pre-departure  
treatment for strongyloidiasis (in all Middle Eastern, Asian, and African refugees) as well 
as for schistosomiasis (in SSA refugees only). This document is an update of the 2005 
guidelines.  
Recommendations for overseas presumptive treatment of intestinal parasites 
 
Refugees originating from the Middle East, Asia, North Africa, Latin America, and the 
Caribbean 
 
Prior to departure for the United States, all refugees originating from the Middle East, 
Asia, North Africa, Latin American, & Caribbean, with exceptions noted in this 
document, should receive presumptive therapy with ivermectin for Strongyloides 
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infection and with albendazole for infections caused by soil-transmitted helminths (Table 
1). Dosing for ivermectin may be based on weight and available tablet size (Table 2).  
 
Refugees originating from sub-Saharan Africa 
 
Soil-transmitted helminths 
All refugees originating from sub-Saharan Africa should receive presumptive therapy 
with albendazole for infections caused by soil-transmitted helminths (Table 1).  
 
Strongyloides 
Refugees from sub-Saharan Africa should also receive presumptive therapy for 
Strongyloides infection with ivermectin (Table 1), but this will depend on whether they 
have originated from or resided in countries where Loa loa is endemic (Box 1).The drug 
of choice for Strongyloides infection is ivermectin. However, cases of encephalopathy 
have occurred in patients treated with ivermectin during large-scale public health 
campaigns in areas of Africa where Loa loa is endemic. Although rare, this reaction is 
related to Loa loa microfilarial load. Therefore, ivermectin should be given only to 
persons originating from Africa who have resided in or come from countries or areas not 
considered endemic for Loa loa (Box 1). Sub-Saharan African refugees who have resided 
in or are coming from areas endemic for Loa loa should not receive presumptive 
ivermectin, and management of Strongyloides should be deferred until they arrive in the 
United States (unless Loa loa is excluded by reviewing a daytime [10 AM to 2 PM] 
Giemsa-stained blood smear). High-dose albendazole (400 mg twice a day for 7 days) is 
an acceptable alternative if Loa loa infection cannot be excluded.  
 
Schistosomiasis  
Refugees from sub-Saharan Africa should also receive presumptive pre-departure therapy 
with praziquantel for schistosomiasis (Table 1). Pre-departure dosing may be based on 
weight and available tablet size (Table 2). If the refugee has never received presumptive 
therapy as part of a mass anti-helminth treatment campaign, and if it is logistically 
feasible, administering praziquantel first, followed by albendazole and ivermectin, may 
reduce the risk of adverse events caused by the release of antigens by dying parasites in 
persons with high parasite loads. However, if the refugee has received previous therapy, 
their parasite load can be assumed to be lower, and there would be no contraindication to 
administering praziquantel together with albendazole and ivermectin. 
 
 
Special instructions for administration of presumptive pre-departure therapy 
 
 Pre-departure regimens for presumptive treatment of intestinal parasites should be 
administered as directly observed therapy. While prescription and first-dose 
observation should be done by medical personnel, subsequent doses can be observed 
by nonmedical staff.  
 Pregnancy testing should be performed before ivermectin or albendazole is 
administered. 
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 Ivermectin and albendazole may be administered concurrently according to World 
Health Organization (WHO) recommendations.  In areas where refugees have 
received previous rounds of mass anti-helminth treatment, ivermectin, albendazole, 
and praziquantel co-administration is well tolerated.
6
 
 Praziquantel may be better tolerated if divided into two doses. 
 There is no known contraindication to co-administration of these intestinal treatment 
regimens with malaria treatment medications. When time allows, spacing may 
improve tolerability. A sample 3-day combined treatment regimen for both parasites 
and malaria is presented in Table 3. 
 
Precautions and contraindications to presumptive treatment 
Children  
 
 Albendazole 
Children <1 year of age should not receive presumptive treatment with 
albendazole. Further information on use of albendazole in pediatric patients 
can be found at the CDC, Division of Parasitic Diseases website. 
 
 Ivermectin 
Children weighing <15 kg or measuring <90 cm should not receive 
presumptive treatment with ivermectin. Further information on use of 
ivermectin in pediatric patients can be found at the CDC, Division of Parasitic 
Diseases website.. 
 
 Praziquantel 
The safety of praziquantel has not been established in children <4 years of age 
or <94 cm in height, so these children should not receive presumptive 
treatment.  Further information on use of praziquantel in pediatric patients can 
be found at the CDC, Division of Parasitic Diseases website.   
 
Pregnant women 
 
 Albendazole 
Albendazole is currently a category C drug in the United States, and it should 
not be administered as presumptive treatment for U.S.-bound refugees during 
any trimester of pregnancy. When a reliable history of the woman’s last 
menstrual period cannot be obtained, a pregnancy test should be performed. 
Pregnant women should have presumptive treatment deferred until after they 
arrive in the United States. Further information on use of albendazole during 
pregnancy can be found at the CDC, Division of Parasitic Diseases website. 
 
 
 Ivermectin 
Ivermectin is a pregnancy category C drug. This medication should not be 
administered as a presumptive medication to a pregnant woman. When a 
reliable history of the woman’s last menstrual period cannot be obtained, a 
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pregnancy test should be performed before presumptive treatment is 
administered.  Further information on use of ivermectin during pregnancy can 
be found at the CDC, Division of Parasitic Diseases website.. 
 
 Praziquantel 
Praziquantel is considered a pregnancy category B drug, and WHO 
recommends the presumptive treatment of pregnant women during any 
trimester of pregnancy in women from schistosomiasis-endemic areas. Further 
information on use of praziquantel during pregnancy can be found at the 
CDC, Division of Parasitic Diseases website. 
 
Women who are breastfeeding 
 
 Albendazole 
Albendazole presumptive therapy may be administered to women who are 
breastfeeding.  Further information on use of albendazole during lactation can 
be found at the CDC, Division of Parasitic Diseases website. 
 
 Ivermectin 
Ivermectin should not be administered to women who are breastfeeding 
during the first week after birth.  Further information on use of ivermectin 
during lactation can be found at the CDC, Division of Parasitic Diseases 
website. 
 
 Praziquantel 
Praziquantel is excreted in low concentrations in human milk. According to 
WHO guidelines for mass prevention campaigns, the use of praziquantel 
during lactation is encouraged. 
7
 For individual patients in clinical settings, 
praziquantel should be used in breast-feeding women only when the risk to the 
infant is outweighed by the risk of disease progression in the mother in the 
absence of treatment. Further information on use of praziquantel during 
lactation can be found at the CDC, Division of Parasitic Diseases website. 
 
 
Refugees with cysticercosis infection 
 
Persons who have neurocysticercosis infection may have seizures following 
treatment with albendazole or praziquantel, since these medications kill Taenia 
solium cysticerci, causing inflammation and provoking seizure activity in the 
brain. The true prevalence of neurocysticercosis in refugee populations is not well 
documented.  Confirmed case reports of adverse events after treatment with 
albendazole or praziquantel remain rare in refugees. Refugees with known 
neurocysticercosis, an unexplained seizure disorder, or subcutaneous nodules 
consistent with cystercercosis should not receive presumptive treatment with 
either albendazole or praziquantel.  
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Physicians should consult the package inserts for additional information about 
ivermectin, albendazole, and praziquantel. 
 
Documentation 
 
Test results and pre-departure treatment should be documented on the Predeparture 
Medical Screening (PDMS) form and placed in the envelope containing the X-ray, which 
is part of the travel packet.  These packets are physically carried by the refugees to the 
United States. If the X-ray envelope is missing, the PDMS form should be placed in a 
separate sealed envelope inside the IOM travel bag, so that this medical information 
about treatment remains confidential.  IOM providers should also enter the information in 
the Migrant Management & Operational Systems Application (MiMOSA) prior to the 
refugees’ arrival, so it can be transmitted to CDC’s Electronic Disease Notification 
(EDN) system.  If treatment was not administered, this should be clearly documented, 
along with the reason that treatment was not administered. For children and pregnant and 
breastfeeding women who do not receive presumptive therapy, the need for subsequent 
treatment should be clearly documented.  
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Table 1.  Recommended medication regimen and standard dosing for presumptive 
treatment of parasitic infections 
 
 
Refugee 
Population 
 
Regimens by Pathogen 
 Soil-transmitted 
helminths:  
Albendazole
1
 
Strongyloidiasis:  
 
Ivermectin
1
 
Schistosomiasis
2
:  
 
Praziquantel
3
 
Adults    
Asia, Middle 
East, North 
Africa, Latin 
American, & 
Caribbean 
400 mg orally for 1 day Ivermectin, 200 
g/kg/day orally once a 
day for 2 days 
Not recommended 
Sub-Saharan 
Africa, non-
Loa loa-
endemic area 
400 mg orally for 1 day
 
 
Ivermectin, 200 
g/kg/day once a day 
for 2 days 
Praziquantel, 40 
mg/kg (may be 
divided and given 
in two doses for 
better tolerance). 
Sub-Saharan 
Africa, Loa 
loa- endemic 
area 
400 mg orally for 1 day 
If Loa loa cannot be 
excluded, treatment 
may be deferred until 
after arrival in the 
United States  
-OR- 
Albendazole 400 mg 
twice a day for 7 days  
Praziquantel, 40 
mg/kg (may be 
divided and given 
in two doses for 
better tolerance). 
Pregnant 
women 
   
Asia, Middle 
East, North 
Africa, Latin 
America & 
Caribbean 
Not recommended Not recommended Not applicable  
Sub-Saharan 
Africa  
Not recommended Not recommended Praziquantel, 40 
mg/kg (may be 
divided and given 
                                                 
1
Although WHO states ivermectin and albendazole may be given concurrently, it is recommended that 
ivermectin be taken on an empty stomach and albendazole with fatty foods. 
 
2
 All sub-Saharan African countries except Lesotho are considered endemic for schistosomiasis. 
 
3
 Praziquantel, if not co-administered, should be administered at least one day prior to either ivermectin or 
albendazole.
  
Praziquantel should be taken with liquids during a meal. 
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in two doses for 
better tolerance). 
Children    
Asia, Middle 
East, North 
Africa, Latin 
America & 
Carribean  
12-23 months of age: 
200 mg orally for 1 
day.
 
Presumptive 
therapy is not 
recommended for any 
infant less than 12 
months of age. 
Ivermectin, 200 
g/kg/day orally once a 
day for 2 days 
Should not be used 
presumptively if <15 
kg  
Not applicable 
Sub-Saharan 
Africa 
12-23 months of age: 
200 mg orally for 1 
day.
 
Presumptive 
therapy is not 
recommended for any 
infant less than 12 
months of age. 
 
Ivermectin, 200 
g/kg/day orally once a 
day for 2 days 
 
Should not be used 
presumptively if <15 
kg or from Loa loa-
endemic country. 
Children under < 4 
years of age should 
not receive 
presumptive 
treatment with 
praziquantel.  Only 
for children from 
sub-Saharan Africa 
 
Table 2. Praziquantel and ivermectin dosing based on weight and tablet size for 
predeparture presumptive treatment of US- bound refugees
 
 
 
 
1
Better tolerated if divided into two doses 
2
Using 600-mg praziquantel tablets  
3
Using 3-mg ivermectin tablets 
Drug and dosing 
Weight 
(kg) 
Praziquantel
1,2
 
Not recommended <15 
1 tablet (600 mg) 15-18 
1 ½ tablets (900 mg) 19-25 
2 tablets (1200 mg) 26-30 
2 ½ tablets (1500 mg) 31-40 
3 tablets (1800mg) 41-50 
4 tablets (2400 mg) 51-69 
5 tablets (3000 mg) > 70 
Ivermectin
3
 
Not recommended <15 
1 tablet (3 mg) 15-24 
2 tablets (6 mg) 25-35 
3 tablets (9 mg) 36-50 
4 tablets (12 mg) 51-65 
5 tablets (15 mg) 66-79 
200 mcg/kg ≥80 
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Table 3. Sample 3-Day Combined Regimen for overseas presumptive treatment of 
parasites and malaria 
 
Presumptive Tx Day Morning Evening* 
Day 1 
Pregnancy Test   
Praziquantel #1 Praziquantel #2* 
Artemether-lumefantrine #1 Artemether-lumefantrine 2* 
Day 2 
Ivermectin #1   
Artemether-lumefantrine #3 Artemether-lumefantrine #4 
Day 3 
Albendazole   
Ivermectin #2   
Artemether-lumefantrine #5 Artemether-lumefantrine #6 
  
*On the first day, praziquantel and artemether-lumefantrine should be administered 8 hours 
following initial dose; on days 2 and 3 should be administered twice a day, morning and evening. 
 
 
 
Box 1.  Endemicity of Loa loa in African countries  
African countries NOT 
considered endemic for Loa 
loa (may use  presumptive 
ivermectin for Strongyloides) 
African countries considered 
endemic for Loa loa 
(presumptive ivermectin  should not be 
used for  Strongyloides) 
Algeria 
Botswana 
Burkina Faso 
Burundi 
Côte d’Ivoire 
Egypt 
Ethiopia 
Eritrea 
Gambia 
Ghana 
Guinea 
Guinea-Bissau 
Kenya 
Liberia 
Libya 
Madagascar 
Malawi 
Mali 
Mauritania 
Mauritius  
Angola 
Cameroon 
Central Africa Republic 
Chad 
Republic of Congo 
Democratic Republic of the Congo 
Equatorial Guinea 
Gabon 
Nigeria  
South Sudan 
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Morocco 
Mozambique 
Namibia 
Niger  
Rwanda 
Senegal 
Sierra Leone  
Somalia 
South Africa 
Sudan 
Swaziland 
Tanzania 
Togo 
Uganda 
Zambia 
Zimbabwe 
